Hello, and welcome to Nutanix Third Quarter 2026 Earnings Conference Call. [Operator Instructions] I would now like to hand the conference over to Rich Valera, Vice President of Investor Relations.
Bristol Myers Squibb (BMY) looks undervalued: 4 near-term pipeline catalysts and DCF imply ~20% upside, plus 4.35% yield.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results